Sam Altman, the CEO of OpenAI, is backing a groundbreaking initiative aimed at extending human lifespan by a decade through ...
Retro Biosciences Inc., a startup using artificial intelligence to discover new drugs, is reportedly raising $1 billion in ...
OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
WIth one foot out the White House door, the Biden administration issued 2 documents Musk is now using in his battle to break ...
Cathie Wood and her Ark Invest funds sold Oklo — the nuclear power startup backed by OpenAI head Sam Altman — and purchased ...
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...